Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## LifeTech Scientific Corporation 先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1302)

## SUPPLEMENTAL ANNOUNCEMENT ON CONNECTED TRANSACTION IN RELATION TO THE TRANSFER OF EQUIPMENT PURSUANT TO THE EQUIPMENT AND COMPONENTS SUPPLY AGREEMENT

Reference is made to the announcement of LifeTech Scientific Corporation (the "Company") dated 28 July 2014 (the "Announcement") in relation to the transfer of equipment pursuant to the Equipment and Components Supply Agreement (the "Transfer"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

Further to the information announced by the Board in the Announcement, the Board would like to provide additional information on the Transfer and the amount of consideration of the Transfer. As disclosed in the Announcement, the Transfer involves (i) the In-Use Equipment and (ii) the Medtronic Singapore Procured Equipment. In the case of the In-Use Equipment, the transfer price will be determined based on the book value of the equipment at the time of transfer of the In-Use Equipment, and in the case of the Medtronic Singapore Procured Equipment, the transfer price will be determined based on the cost of procurement.

Besides, the Board expects that the Transfer will take place by the end of April 2015. The Company estimates that even if the In-Use Equipment is calculated at costs, the estimated maximum consideration that will be payable in cash to Medtronic Singapore Operations Pte Ltd. for the transfer of all of (i) the In-Use Equipment and (ii) the Medtronic Singapore Procured Equipment will not exceed USD562,000.

The Directors (including the independent non-executive Directors) are of the view that the Transfer under the Equipment and Components Supply Agreement and the terms of the transactions contemplated thereunder have been entered into in the ordinary and usual course of business of the Group and on normal commercial terms, and the terms are fair and reasonable and in the interests of the Shareholders as a whole.

As the applicable percentage ratios under Rule 14.07 of the Listing Rules in respect of the Transfer do not exceed 5%, the Transfer does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

By order of the Board

LifeTech Scientific Corporation

XIE Yuehui

Chairman and Executive Director

Hong Kong, 7 August 2014

As at the date of this announcement, the executive Directors of the Company are Mr. XIE Yuehui and Mr. ZHAO Yiwei Michael; the non-executive Directors of the Company are Mr. WU Jianhui, Mr. MARTHA Geoffrey Straub, Dr. LIDDICOAT John Randall and Mr. JIANG Feng; and the independent non-executive Directors of the Company are Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Gengshen and Mr. ZHOU Luming.